961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapyIván Márquez‐Rodas, Stéphane Dalle, Pablo Cerezuela‐Fuentes et al.|Unknown|2021Cited by 8
BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203Iván Márquez‐Rodas, Stéphane Dalle, Caroline Dutriaux et al.|Journal of Clinical Oncology|2025Cited by 7
Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 studyIván Márquez‐Rodas, Stéphane Dalle, Caroline Dutriaux et al.|Cancer Research|2022Cited by 6
Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapyIván Márquez‐Rodas, Marisol Quintero, Miguel Fernández de Sanmamed Gutiérrez et al.|Cancer Research|2021Cited by 2